8-K: HealthLynked Appoints Jeremy Daniel as New CFO, Replacing David Rosal

HealthLynked Corp. announces the appointment of Jeremy Daniel as its new Chief Financial Officer, effective January 15, 2025, replacing David Rosal, who resigned.

Summary

• HealthLynked Corp. has appointed Jeremy Daniel as its new part-time Chief Financial Officer, effective January 15, 2025.
• Mr. Daniel will work two days per week with a base salary of $66,000 per year.
• He has previously served as CFO for Innoveren Scientific, Regenerative Medicine Solutions, and Sleep Apnea Treatment Centers of America, and as Controller for Omnicare.
• David Rosal resigned as Chief Financial Officer, effective January 15, 2025, with the resignation not due to any disagreement with the company.
• HealthLynked's CEO, Michael Dent, expressed enthusiasm for Mr. Daniel's appointment, citing his experience in financial operations and strategic planning.
• Mr. Daniel has experience raising over $100M in funding through public and private equity markets and executing pivotal mergers and acquisitions.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the appointment of an experienced CFO and management's optimistic outlook. However, the presence of forward-looking statements and associated risks tempers the overall sentiment.

Positives

• HealthLynked has appointed an experienced CFO with a strong background in financial management and strategic planning.
• Jeremy Daniel has a proven track record of raising capital and executing mergers and acquisitions.
• The appointment is expected to strengthen HealthLynked's executive leadership and support the company's growth initiatives.
• Mr. Daniel's experience includes leading financial systems in compliance with GAAP and SEC regulations.

Risks

• The press release contains forward-looking statements that are subject to risks and uncertainties.
• Actual results may differ materially from those expressed or implied by these statements.
• The company's filings with the SEC contain a description of certain risks and uncertainties applicable to its operations.

Future Outlook

The company aims to revolutionize healthcare through technology and create a more efficient and patient-centric healthcare system.

Management Comments

• Michael Dent, M.D., CEO of HealthLynked, stated that Jeremy Daniel's experience and leadership make him an outstanding addition to the team.
• Jeremy Daniel expressed his excitement about contributing to HealthLynked's mission and enhancing financial strategies.

Industry Context

The appointment of a new CFO reflects HealthLynked's ongoing efforts to strengthen its leadership team and drive growth in the competitive healthcare technology sector.

Comparison to Industry Standards

• It is difficult to compare HealthLynked's CFO compensation directly to industry standards without knowing the company's size and revenue.
• However, the appointment of a part-time CFO is not uncommon for smaller companies or those in a growth phase.
• Innoveren Scientific, where Mr. Daniel previously served, is a publicly traded biotech firm, suggesting he has experience in a similar industry.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of a new CFO as a positive step towards strengthening the company's financial management.
• Employees may be affected by changes in financial strategy and operations under the new CFO's leadership.

Key Dates